Samsung Biologics

104 articles about Samsung Biologics

• Samsung BioLogics to Showcase End-to-End CDMO Capabilities at BIO International 2019

  5/29/2019

  For the eighth consecutive year since the company's foundation in 2011, Samsung BioLogics will be showcasing its full end-to-end CDMO capabilities at the BIO International 2019 convention in Philadelphia, PA, June 3rd to 6th.

• Samsung BioLogics Wins 2019 CMO Leadership Awards in All Six Core Categories Three Years in a Row

  3/21/2019

  Samsung BioLogics is pleased to announce that Samsung has won CMO Leadership Awards for all six core categories for the third year in a row in the 8th annual CMO Leadership Awards Reception presented by Life Science Leader.

• 

  Samsung Bioepis' First Cancer Biosimilar Approved by the FDA

  1/21/2019

  The U.S. Food and Drug Administration (FDA) approved South Korea’s Samsung Bioepis’ Ontruzant (trastuzumab-dttb), a biosimilar to Genentech’s Herceptin (trastuzumab).
• 

  15 Massachusetts Life Science Companies That Spend the Most on R&D

  11/8/2018

  Boston Business Journal recently created a list of 15 Massachusetts life science companies that in their third-quarter reports, allocated the highest percentage of total costs to research and development. Here’s a look.
• 

  Biogen Ups Investment in Biosimilar Drug Maker Samsung Bioepis by $700 Million

  11/7/2018

  Cambridge, Mass.-based Biogen exercised its option to acquire additional shares of South Korea’s Samsung Bioepis. Samsung Bioepis focuses on developing biosimilar drugs and is a joint venture between Samsung Biologics and Biogen formed in 2012.

• Samsung BioLogics Streamlines Quality Document Management Globally With Veeva Vault QualityDocs

  7/18/2018

  Biopharmaceutical company improves real-time visibility into quality documents

• 

  Biogen Increases Ownership in Samsung Bioepis

  6/29/2018

  Cambridge, Massachusetts-based Biogen exercised its option to acquire additional shares of Samsung Bioepis, a joint venture with Samsung BioLogics that was founded in 2012.

• Samsung BioLogics Receives an additional FDA Approval for its world largest Plant's Production

  5/24/2018

  3rd approval for Plant 2 in just 26 months since GMP ready

• Samsung Announces Commitment to Lower Dose Exposure Within its Digital Radiography Suite

  4/24/2018

  Portfolio presenting GC85A with Image Post-processing Engine (IPE) S-Vue™3.02 for greater diagnostic confidence with 50% dose reduction*

• MilliporeSigma and Samsung BioLogics to Extend Strategic Alliance

  11/1/2017

  MilliporeSigma today announced the signing of a Memorandum of Understanding with Samsung BioLogics for a strategic alliance on biopharma manufacturing and biologics process development.

• Samsung Biologics Receives The 1st FDA Approval At The World's Largest Plant

  10/12/2017

• Sun Pharma & Samsung Biologics Announce Strategic Manufacturing Tie-Up For Tildrakizumab

  7/5/2017

• Week In Review: Investors Embrace Future Of Biologics Drugs In Samsung Biologics ' $2 Billion IPO

  11/14/2016

• Samsung Biologics Raises $2 Billion In Korean IPO

  11/14/2016

• Samsung Biologics 's Next Cash Cow Could Be This $8 Billion Contract Drugmaker

  11/11/2016

• Bloomberg: Samsung Biologics And Wuxi Biologics Plan IPOs For their Biologic CMOs

  10/17/2016

• Human Genome, DNA, The New Themes Of Samsung Biologics Focuses

  9/30/2016

• Week In Review: Korea's Samsung Biologics Files For $2.5 Billion IPO

  8/15/2016

• Samsung Biologics Seeks To Raise Up To $2.5 Billion From IPO

  8/10/2016

• Samsung Biologics Eyes $2.6 Billion IPO in Korea This Year

  4/28/2016